Armon Sharei

Armon Sharei is the founder and CEO of Portal Biotechnologies, a cell-engineering platform company in Watertown, Massachusetts that builds devices to push genetic and molecular cargo into living cells without killing them. He earned a chemical engineering PhD at MIT, where he invented the membrane-squeezing CellSqueeze technique, then founded SQZ Biotechnologies, raised more than $300M, struck a billion-dollar Roche partnership, and took the company public on the NYSE in 2020 before being ousted and watching it liquidate in 2024. After a sabbatical spent drawing comics about immune cells, he returned with Portal, choosing this time to sell tools rather than develop drugs, and has built a network of 100+ customers including most of the top 10 global pharma companies plus an $8M DARPA contract.